Literature DB >> 25143419

Reply to "molecular diagnosis of rifampin-monoresistant tuberculosis in Indian patients: problems with a discordance analysis".

Sarman Singh1, Syed Beenish Rufai2, Parveen Kumar2, Jitendra Singh2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25143419      PMCID： PMC4313201          DOI： 10.1128/JCM.01731-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  12 in total

1.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

2.  High degree of multi-drug resistance and hetero-resistance in pulmonary TB patients from Punjab state of India.

Authors:  Parveen Kumar; Veena Balooni; Brijesh Kumar Sharma; Virender Kapil; K S Sachdeva; Sarman Singh
Journal:  Tuberculosis (Edinb)       Date:  2013-10-22       Impact factor: 3.131

3.  Molecular diagnosis of rifampin-monoresistant tuberculosis in Indian patients: problems with a discordance analysis.

Authors:  David Alland; Joy S Michael; Claudia M Denkinger; Daniela M Cirillo
Journal:  J Clin Microbiol       Date:  2014-09       Impact factor: 5.948

4.  Described diagnostic inconsistencies were observed with an obsolete version of the Xpert MTB/RIF assay and are unlikely to recur in the current version of the assay.

Authors:  Robert Blakemore; David Alland
Journal:  J Clin Microbiol       Date:  2014-02       Impact factor: 5.948

5.  Reply to "described diagnostic inconsistencies were observed with an obsolete version of the Xpert MTB/RIF assay and are unlikely to recur in the current version of the assay".

Authors:  Akos Somoskovi; Guido V Bloemberg
Journal:  J Clin Microbiol       Date:  2014-02       Impact factor: 5.948

Review 6.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

7.  Molecular characterization of Mycobacterium tuberculosis isolates from North Indian patients with extrapulmonary tuberculosis.

Authors:  Manimuthu Mani Sankar; Jitendra Singh; Selvaraj Cynthiya Angelin Diana; Sarman Singh
Journal:  Tuberculosis (Edinb)       Date:  2012-11-07       Impact factor: 3.131

8.  Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes.

Authors:  Nicola M Zetola; Sanghyuk S Shin; Kefentse A Tumedi; Keletso Moeti; Ronald Ncube; Mark Nicol; Ronald G Collman; Jeffrey D Klausner; Chawangwa Modongo
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

9.  Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso.

Authors:  L Sangaré; S Diandé; G Badoum; B Dingtoumda; A S Traoré
Journal:  Int J Tuberc Lung Dis       Date:  2010-11       Impact factor: 2.373

10.  Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods.

Authors:  Dorte Bek Folkvardsen; Vibeke Ø Thomsen; Leen Rigouts; Erik Michael Rasmussen; Didi Bang; Gertjan Bernaerts; Jim Werngren; Juan Carlos Toro; Sven Hoffner; Doris Hillemann; Erik Svensson
Journal:  J Clin Microbiol       Date:  2013-09-25       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.